Assessment the effect of Gabapentin in the treatment of chronic non-bacterial prostatitis

Assessment the effect of Gabapentin as an assistive treatment in chronic nonbacterial prostatitis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180103038196N7

Enrollment

100

Registered

2019-02-28

Start date

2018-02-20

Completion date

Unknown

Last updated

2019-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic nonbacterial prostatitis. Chronic prostatitis

Interventions

Intervention group: Patients with non-bacterial chronic prostatitis.the patient will receive Gabapentin capsules produced by abidi Company at a dose of 100 mg orally twice daily. The treatment period

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age 18 or more Having pain in one or more areas of the groin,hypo-gastric, back pain, testicular, penis, lower back, anal, and the area between the scrotum and anus for at least three months Having one or more of the following urinary symptoms that include: dysuria, frequency, delay in beginning urination, enuresis, the urgency for urination Painful ejaculation Erectile dysfunction

Exclusion criteria

Exclusion criteria: Chronic bacterial prostatitis Acute prostatitis Dissatisfied to participate in the study Allergy to Gabapentin

Design outcomes

Primary

Measure	Time frame
Reducing the pain caused by non-bacterial chronic prostatitis. Timepoint: Evaluation of pain after 12 weeks of treatment. Method of measurement: Visual Analogue Scale for pain.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNiloufar Tajali

Islamic Azad University

salimia92@yahoo.com+98 23 3236 3433

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026